Global Prophylaxis of Organ Rejection Market is growing with factors such as the increased prevalence of organ transplantation, rise in surgical procedures, rise in recipient population and product launches. However, the factors that are expected to restrain the market are the rise in the cost of the transplantation procedure, lack of awareness about organ transplantation and the risks included while the patient receives the transplanted organ.
Global Prophylaxis of Organ Rejection Market Scenario
According to Data Bridge Market Research, the region which is dominating the global prophylaxis of organ rejection is North America. Astellas Pharma Inc. is dominating in North America, with a market share of 49.07%, since its major product prograf and advagraf (tacrolimus) are being used by transplant patients for organ rejection in North America.
- In July 2021, Astellas Pharma Inc. had received the Food and Drug Administration (FDA) approval for prograf. Prograf is the drug which is being used to avoid rejection of new lung transplant. The approval received resulted in recommendation of prograf for use in liver, kidney and heart transplants to adult and paediatric patients
Trends Impacting the Market
Now the question is which other regions is Astellas Pharma Inc. F. Hoffmann-La Roche Ltd and Bristol-Myers Squibb Company targeting? Data Bridge Market Research has estimated a large growth in North America. North America prophylaxis of organ rejection market and the market leaders targeting the U.S., Canada, and Mexico, to be their next pocket revenue for 2022.
Global prophylaxis of organ rejection market is becoming more competitive with companies such as Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company. These are the top dominating companies in prophylaxis of organ rejection market and are launching more new drugs for organ rejection in the market. Data Bridge Market Research new reports highlight the major growth factors and opportunities in the global prophylaxis of organ rejection market.
For more analysis on the global prophylaxis of organ rejection market request for a briefing with our analysts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-prophylaxis-of-organ-rejection-market
Global Prophylaxis of Organ Rejection Market Developments
- In December 2021, Bristol-Myers Squibb Company, had received the Food and Drug Administration (FDA) approval for orencia (abatacept). Orencia (abatacept) is combined with a calcineurin inhibitor and methotrexate for the prevention of acute graft versus host disease (agvhd) in patients undergoing hematopoietic stem cell transplant. The approval received would make orencia (abatacept), become an important treatment option for prevention of liver rejection. The orencia (abatacept), would be able to fulfil the unmet medical need for organ rejection
- In September 2020, F. Hoffmann-La Roche Ltd, had received the Food and Drug Administration (FDA) approval for BK virus quantitative test on cobas 6800/8800 Systems. The BK virus quantitative test, is used to provide optimum care for transplant patients. The approval received would improve the treatment plan for patients, undergoing organ transplantation. BK virus quantitative test can simultaneously monitor and improve care for transplant patients who are at risk for these common infections
Scope of the Global Prophylaxis of Organ Rejection Market.
Global prophylaxis of organ rejection market is segmented on the basis of countries, which are U.S., Canada, and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Ireland, Belgium, Netherland, Switzerland, and the rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific. Brazil, Argentina, and Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest Of Middle East And Africa. All country-based analysis of global prophylaxis of organ rejection market is further analyzed based on further segmentation.
The global prophylaxis of organ rejection market is categorized into seven segments: cause, treatment, route of administration, organ, patient type, end user and distribution channel. On the basis of cause, the global prophylaxis of organ rejection market is segmented into epidemiologic exposure, antibacterial prophylaxis, prophylaxis against other pathogens and others. The epidemiologic exposures are further sub-segmented into hospital exposure and community exposure. The anti-bacterial prophylaxis is further sub-segmented into perioperative antibacterial prophylaxis and post-transplant prophylaxis. In 2022, the epidemiologic exposure segment is expected to dominate the global prophylaxis of organ rejection market due to availability of direct information and presence of pathogens related to prophylaxis of organ rejection in the U.S.
To know more about the study https://www.databridgemarketresearch.com/reports/global-prophylaxis-of-organ-rejection-market
Key Pointers Covered in Global Prophylaxis of Organ Rejection Market Industry Trends and Forecast to 2029
- Market Size
- Top to Bottom Market Analysis
- Recent Developments for Market Competitors
- Recent Market Value for Different Countries
- Market value and over view of prophylaxis of organ rejection market
- Company profiling of top eight players of prophylaxis of organ rejection market.
Key Market Competitors Covered in the Report
- Ossium Health, Inc.
- Alphamab Oncology
- Altavant Sciences, Inc.
- Hansa Biopharma.
- Concord Biotech
- Panacea Biotec
- WOCKHARDT.
- SEBELA PHARMACEUTICALS
- Accord-UK Ltd.
- Veloxis Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Dr Reddy’s Laboratories, Ltd.
- Viatris Inc.
- Strides Pharma Science Limited.
- Glenmark
- Biocon.
- Pfizer Inc.
- Mayne Pharma Group Limited
- Hikma Pharmaceuticals PLC
- AbbVie Inc
- Apotex Inc.
- Teva Pharmaceutical U.S.A Inc.
- Amneal Pharmaceuticals LLC.
- Zydus Pharmaceuticals, Inc.
- Novitium Pharma.
- ZHEJIANG HISUN PHARMACEUTICAL Co., LTD.
- F. Hoffmann-La Roche Ltd
- CSL Behring
Above are the key players covered in the report, to know about more and exhaustive list of the global prophylaxis of organ rejection market companies’, contact us https://www.databridgemarketresearch.com/toc/?dbmr=global-prophylaxis-of-organ-rejection-market
Research Methodology: Global Prophylaxis of Organ Rejection Market.
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Primary Respondents
- Demand Side: Chief Level Officers, Product and Marketing Manager, Manufacturers, Distributors, Buyers, Sales Technical Team.
- Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Related Reports
- Global Organ Transplantation Market - Industry Trends and Forecast to 2027
- Global Immunosuppressant Market - Industry Trends and Forecast to 2028
- Colombia Organ Transplant Immunosuppressant Drugs Market - Industry Trends and Forecast to 2027
- Global Cyclosporine Market - Industry Trends and Forecast to 2027
- Global Sirolimus Market - Industry Trends and Forecast to 2027
- Global Knee Osteoarthritis Market - Industry Trends and Forecast to 2027
Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/
